Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, and advisor to MedTech suppliers, highlights a key new senior appointment by the UK medical devices regulator.
The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Professor Jacob George as its first ever Chief Medical and Scientific Officer, a new senior role intended to lead the agency’s scientific agenda and shape regulation across the UK. Professor George will split his time between the MHRA’s London office and its science campus in Hertfordshire while retaining his home base in Scotland.
Professor George currently serves as Professor of Cardiovascular Medicine and Therapeutics at the University of Dundee Medical School and is consultant physician and clinical lead for the Cardiovascular Risk service in NHS Tayside. He is qualified in Clinical Pharmacology and General Internal Medicine and is an accredited European Hypertension Specialist.
The MHRA described the role as pivotal to driving scientific excellence and implementing the MHRA science strategy, with responsibilities that include leading the agency’s Science Campus and directing science and innovation strategies that underpin regulatory decision-making.
The agency’s Chair, Professor Anthony Harnden, welcomed the appointment, saying Professor George’s combined clinical and academic experience will be invaluable in protecting and promoting public health and in ensuring public confidence in medicines and healthcare products.
Lawrence Tallon, MHRA Chief Executive, said Professor George will be “a prominent voice for the MHRA,” championing effective regulation, patient safety, and the UK’s standing in the global life sciences sector. Tallon emphasised that Professor George’s remit will extend to shaping the MHRA’s science and innovation priorities at a time when rapid technological and scientific advances are reshaping medicines regulation.
Professor George said he was “delighted to be joining the MHRA at an important time for the agency and the UK life sciences sector.” He highlighted the agency’s influence on the safety and effectiveness of medicines, vaccines and health technologies used by millions across the UK, and said he looked forward to contributing to high-quality patient care and life sciences innovation.
The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
Related
The post New voice for innovation at the heart of the MHRA first appeared on TechToday.
This post originally appeared on TechToday.